Condition: Non-small Cell Lung Cancer · Sponsor: Changzhou No.2 People's Hospital
This study plans to reconstruct intestinal microecology through fecal microbiota transplantation (FMT), and combine with standard first-line therapy to enhance the anti-tumor immune effect at the same time, thereby extending the progression-free survival of patients and improving the prognosis of patients.
This description comes directly from the study's public registry record.
Hua Jiang, MD · +86-18015852711 · czeyjh@njmu.edu.cn
Always discuss trial participation with your own doctor first.
| Changzhou No.2 Poeple's Hospital | Changzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06403111